pharmaceutical investing Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results
pharmaceutical investing Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School
Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016
Mustang Bio Announces Oral Presentation of Initial Clinical Data for MB-101 (IL13Ra2-specific CAR T cells) by City of Hope Investigators at the American Society of Gene and Cell Therapy 19th Annual Meeting
Silver Hammer Plans a Fall Surface and Drilling Exploration Program at the Silver Strand Project in Idaho, USA
Blue Jay Gold Intersects 14.0 m of 6.15 g/t Gold and 124 g/t Silver at Skukum Creek, Including 10.5 m of 7.84 g/t Gold and 154 g/t Silver
Blackrock Silver Receives Conditional Approval to List on The TSX and Establishes ATM Program as Longer Term Financial Alternatives
